Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Firms Will Benefit From Cautious Estimates Of Part D Impact – Analyst

Executive Summary

Drug manufacturers' conservative estimates about the impact of the Medicare prescription drug benefit will pay off in 2006, Alliance analyst Norm Fidel suggested at the JP Morgan Healthcare conference Jan. 12

You may also be interested in...

Pharma CEOs Plugged In To Medicare

Below are excerpts from remarks on Medicare Part D made by executives at the Jan. 4-5 Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York. Most CEOs are sticking with conservative forecasts for now that Medicare will have at most a modest impact on their business. While Merck and GlaxoSmithKline did not mention Medicare in their presentations, Pfizer devoted most of its talk to Part D, reporting that it is "retooling" to take advantage of Medicare opportunities.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts